



**LasMed LLC**

**Contact:** Mike Nemenov

**Location:** Mountain View, CA 94043

**Email:** mnemenov@lasmed-online.com

**Tel:** (650) 996-3380

**Website:** lasmed-online.com



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

**National Institutes of Health**



**National Institutes of Health Commercialization Assistance Program (NIH-CAP)**

## Company Profile

**Industry Sector:** Biological Research Tools and Medical Devices

**Company Overview:** LasMed LLC has pioneered the development of diode laser-based stimulators for selective activation of pain through Adelta/C small nerve fibers and TRPV positive DRG/HEK cells. The main implementations of this technology are basic research, clinical and preclinical trials of analgesics in development, and diagnosis of diabetic, HIV, herpes, cancer neuropathies and pain.

**Target Market(s):** Academic laboratories, pharmaceutical companies, contract research organizations, clinical laboratories, neurology and pain management departments.

## Key Value Drivers

**Technology\*:** The LasMed stimulators test functionality of small nerve fibers (A-delta or/and C). The stimulators are compatible with real-time imaging (fMRI, LEP/EEG, MEG) and quantitative sensory tests (QST) for pain research and diagnosis of small nerve fiber neuropathies in humans and animals.

**Competitive Advantage:** LasMed technology and pain protocols are the only ones in existence that offer selective activation of A-delta or C small fibers, independently of their depth, location and in any body part. Their translational properties can be utilized in both preclinical trials and in the clinic. The technology is protected by US patents.

**Plan & Strategy:** Obtain strong efficacy and safety data, then identify a strategic partner to complete clinical development and launch product.

\*Technology funded by the NIDA & NINDS and being commercialized under the NIH-CAP

## Management

### Leadership:

Mike Nemenov, PhD: President and Chief Scientific Officer  
Vivian Lauderdale, MBA, MS, RAC: VP Regulatory Affairs & Quality Assurance  
John Ross: Business strategy and IP attorney

### Scientific Advisory Board:

David Yeomans, PhD: Professor, Director of Pain Research, Stanford University,  
Miroslav "Misha" Backonja, MD: Director of Neuroscience, CRILifetree

## Product Pipeline

Products	2013-2015	2015-2016	2018-2019
Bio-research stimulator	SBIR Phase IIB to develop and validate a commercializable low cost diode laser stimulator for preclinical research	Production and Marketing	
Medical stimulator	SBIR Phase IIB to develop and validate a commercializable medical selective diode laser stimulator for clinical research	FDA clearance	
		for clinical research	for clinic including billing code